Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey P Meyers

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Statistical Methods in Medical Research|June 1, 2022
Conversion of non-inferiority margin from hazard ratio to restricted mean survival time difference using data from multiple historical trialsRuizhe Chen, Sanjib Basu, Jeffrey P Meyers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2022
Reply to A. Smith et alElisa Fontana, Jeffrey P Meyers, Thierry André, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling MethodsMing-Wen An, Yu Han, Jeffrey P Meyers, et al.
Journal of Surgical Oncology|May 30, 2019
A nomogram for predicting survival and retroperitoneal lymph node dissection treatment in patients with resected testicular germ cell tumorsYougen Wu, Jeffrey P Meyers, Guowei Shi, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|July 23, 2013
Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literatureKrishna Patel, Nathan R Foster, Ann Farrell, et al.
The Oncologist|January 26, 2019
A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)Thorvardur R Halfdanarson, Nathan R Foster, George P Kim, et al.
Journal of Geriatric Oncology|December 9, 2014
Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysisWilliam G Rule, Nathan R Foster, Jeffrey P Meyers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2014
Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials ProgramChristopher H Lieu, Lindsay A Renfro, Aimery de Gramont, et al.
Cancer Causes & Control : CCC|May 27, 2019
Development and validation of a model to predict outcomes of colon cancer surveillanceJohnie Rose, Laura Homa, Chung Yin Kong, et al.
JAMA Oncology|December 23, 2016
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical TrialsFrank A Sinicrope, Qian Shi, Carmen J Allegra, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Statistical Methods in Medical Research|June 1, 2022
Conversion of non-inferiority margin from hazard ratio to restricted mean survival time difference using data from multiple historical trialsRuizhe Chen, Sanjib Basu, Jeffrey P Meyers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2022
Reply to A. Smith et alElisa Fontana, Jeffrey P Meyers, Thierry André, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling MethodsMing-Wen An, Yu Han, Jeffrey P Meyers, et al.
Journal of Surgical Oncology|May 30, 2019
A nomogram for predicting survival and retroperitoneal lymph node dissection treatment in patients with resected testicular germ cell tumorsYougen Wu, Jeffrey P Meyers, Guowei Shi, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|July 23, 2013
Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literatureKrishna Patel, Nathan R Foster, Ann Farrell, et al.
The Oncologist|January 26, 2019
A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)Thorvardur R Halfdanarson, Nathan R Foster, George P Kim, et al.
Journal of Geriatric Oncology|December 9, 2014
Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysisWilliam G Rule, Nathan R Foster, Jeffrey P Meyers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2014
Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials ProgramChristopher H Lieu, Lindsay A Renfro, Aimery de Gramont, et al.
Cancer Causes & Control : CCC|May 27, 2019
Development and validation of a model to predict outcomes of colon cancer surveillanceJohnie Rose, Laura Homa, Chung Yin Kong, et al.
JAMA Oncology|December 23, 2016
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical TrialsFrank A Sinicrope, Qian Shi, Carmen J Allegra, et al.
Pageof 3